论文部分内容阅读
目的:对应用拉米夫定与阿德福韦酯联合对患有活动性乙肝肝硬化疾病的患者实施治疗的临床效果进行研究。方法:将我院收治的92例患有活动性乙肝肝硬化疾病的患者随机分为对照组和治疗组,平均每组46例。单纯采用拉米夫定对对照组患者实施治疗;采用拉米夫定与阿德福韦酯联合对治疗组患者实施治疗。结果:治疗组患者活动性乙肝肝硬化疾病治疗效果明显优于对照组;肝功能指标恢复正常时间和用药方案临床实施总时间明显短于对照组。结论:应用拉米夫定与阿德福韦酯联合对患有活动性乙肝肝硬化疾病的患者实施治疗的临床效果非常明显。
OBJECTIVE: To study the clinical effects of lamivudine and adefovir dipivoxil in the treatment of patients with active hepatitis B cirrhosis. Methods: 92 patients with active hepatitis B cirrhosis who were admitted to our hospital were randomly divided into control group and treatment group with an average of 46 cases in each group. The patients in the control group were treated with lamivudine alone, and the patients in the treatment group were treated with lamivudine and adefovir dipivoxil. Results: The therapeutic effect of active hepatitis B cirrhosis disease in treatment group was better than that in control group. The time of returning normal liver function and the total time of clinical application of medication regimen was significantly shorter than that of control group. Conclusion: The clinical effect of lamivudine combined with adefovir dipivoxil in the treatment of patients with active hepatitis B cirrhosis is very obvious.